Merck and Insilico Make Deals, Claude Science’s Debut, Vaccines for Neglected Diseases
About this episode
The episode discusses recent biotech deals, AI collaborations for drug discovery, and vaccine developments for neglected diseases.
More big biotech deals on the docket this week. First, Merck KGaA is buying Bio-Techne for $11.3 billion to expand its presence in high-growth life science markets. We dive into the details of this deal and then turn our attention to a $2.5 million collaboration to use artificial intelligence to find drug candidates for neuroimmune disorders. That deal involves Insilico Medicine and SK Biopharmaceuticals. Still on the theme of AI, we discuss Anthropic’s Claude Science, the latest entrant to the growing ecosystem of tech platforms specialized for biology, and a set of models for antibiotic design and vaccine target prediction. Lastly, we dig into two recent publications that discuss vaccines for Nipah virus and one of its relatives, and for treating schistosomiasis. Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base : Merck KGaA to Acquire Bio-Techne for $11.3B, Expanding Life Science Tools Presence By Alex Philippidis, GEN Edge , June 25, 2026 Insilico, SK Launch…
More episodes of Touching Base
- Parkinson’s in the Clinic, Insilico enters Phase III, Vertex Acquires Crinetics
- Historic Biotech IPO, Merck, Protillion’s AI Deal, Testing a Lassa–Rabies Vaccine
Explore listener stats, chart rankings, contacts and more on the Touching Base podcast page.